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Medically inoperable peripheral lung cancer
treated with stereotactic body radiation therapy
K. D. Kelley1, D. L. Benninghoff2, J. S. Stein3, J. Z. Li2, R. T. Byrnes2, L. Potters1, J. P. S. Knisely1 and H. D. Zinkin2,4*

Abstract
Background: Lung cancer is the most frequent cause of cancer-related death in North America. There is wide
variation between patients who are medically inoperable and those managed surgically. The use of stereotactic
body radiotherapy (SBRT) has narrowed the gap in survival rates between operative and non-operative management
for those with early stage disease. This retrospective study reports outcomes for the treatment of peripheral non-small
cell lung carcinoma (NSCLC) with SBRT from a single community practice.
Methods: Sixty-seven consecutive patients (pts) with inoperable, untreated peripheral lung tumors were treated from
2010 through 2012 and included in this study. Stereotactic targeting was facilitated by either spine or lung-based
image guidance, either with or without fiducial marker tracking with a frameless robotic radiosurgery system. Peripheral
tumors received a median biological effective dose (BED) of 105.6 Gy10 or in terms of a median physical dose, 48 Gy
delivered over 4 daily fractions. Survival was measured using the Kaplan-Meier method to determine rates of local
control, progression of disease and overall survival. The Cox proportional hazards regression model was used to study
the effects of tumor size, stage, histology, patient age, tumor location (lobe), tracking method, and BED on the survival
distributions.
Results: The median follow-up for this cohort was 24.5 months (range: 2.4–50.3) with an overall (OS) 3-year survival of
62.4 % (95 % CI: 74.3-47.3). The median progression-free survival was 28.5 months (95 % CI: 15.8 months to not
reached). Local control (LC), defined as a lack of FDG uptake on PET/CT or the absence of tumor growth was achieved
in 60 patients (90.9 %) at the time of first follow-up (median 3 months, range: 1–6). Local control at one year for the
entire cohort was 81.8 % (95 % CI, 67.3-90.3). The one-year OS probability among those who achieved local control at
first follow-up was 86.2 % (95 % CI, 74.3-92.9) but no patients who did not achieve LC at first follow-up survived one
year. Of the 60 pts that achieved initial LC, 16 have died. The rates of local control, progression-free survival and overall
survival were not statistically different for patients treated using a fiducial target tracking system versus non-invasive
guidance. (p = 0.44, p = 0.97 and p = 0.66, respectively). No National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE-4) grade 3 or greater toxicity was observed.
Conclusion: SBRT is an effective treatment for medically inoperable NSCLC patients with peripherally located tumors.
This therapy appears to be well tolerated with low toxicity, and patient outcomes when using non-invasive tumor
tracking systems are not inferior to traditional fiducial-based techniques.
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Background
Until the advent of stereotactic body radiation therapy
(SBRT), patients with early and intermediate stage lung
cancer who were medically inoperable had limited treatment options [1]. Traditional protracted radiotherapy
yielded relatively poor outcomes for this patient population historically with a 5-year overall survival of only
13–39 % [2]. Sophisticated treatment planning and
image guidance now permits focal high-dose per fraction radiation to be delivered safely [3, 4]. This approach
of dose escalation delivered to a defined target while
preserving adjacent healthy tissues with strict geometric
avoidance of organs at risk (OARs) is what constitutes
SBRT. Clinical trials have shown an improvement of the
therapeutic ratio compared to results from conventional
radiotherapy with enhanced control rates and low toxicity to OARs [1, 5–11]. This approach has in turn
proven very effective in controlling tumors in medically
inoperable patients and is now considered a standard of
care for this patient population [1].
The purpose of this study was to analyze the outcomes
of patients treated with SBRT for early and intermediate
stage NSCLC within a community-based setting, in
order to outline potential prognostic factors and assess
variations in survival and local control rates when using
different methods of image guidance. Moreover, data analyzed from a community-based practice may better estimate non-academic centers’ outcomes and be more
representative of likely outcomes outside tertiary centers.
Additionally, lower dose per fraction regimens, similar
to those used in this study and known to carry less risk
of inducing acute and long-term toxicities, are hypothesized to be more routinely used in a community setting,
as opposed to higher dose-escalation strategies reported
by many early multi-institutional series done at large
academic centers [1, 12].
Here we outline as our primary endpoint, all-cause
mortality reported as overall survival of the entire cohort
measured from the time of therapy completion. Other
endpoints include disease-free survival, local control, and
correlations between local control and overall survival
including tumor size, histology, tumor location, and treatment technique.

variables were collected during the analysis: date of treatment, patient age, tumor histology, tumor size, technique
of treatment, tumor location, length of follow-up, toxicity,
tumor control, and survival. IRB policies were followed
regarding data deidentification.

Methods
Study approval was obtained from the North Shore-LIJ
Health System (NSLIJHS), Monter Cancer Center Scientific Advisory Committee. A retrospective chart review
protocol was further reviewed and approved by the
NSLIJHS Institutional Review Board (IRB). Thereafter, a
database of all patients diagnosed with lung cancer and
treated with radiosurgery at North Shore Radiation
Therapy from 2010 to 2012 was created to allow for at
least a minimum of 2 years of follow-up. The following

Radiotherapy technique and specifications

Due to the presence of a collaborative thoracic oncology
program with prospective review, each patient was evaluated by a multidisciplinary team including a thoracic
surgeon, interventional radiologist, medical and radiation
oncologists. Patients were deemed medically inoperable
based on objective criteria including a FEV1 < 1.5 L, preoperative FEV1 < 40 % predicted value or DLCO <40 % of
predicted value and at the final discretion of the surgeon.
Many patients included in this study had fiducial markers
placed by interventional radiology at the time of tumor biopsy unless they were deemed too high risk for this procedure. All patients were then simulated on a GE
Lightspeed 64 slice 4D CT simulator and treated at North
Shore Radiation Therapy/Cyberknife of Long Island. Target structures were delineated on pulmonary CT windows
with the aid of PET fusion. Avidity (a sustained uptake
value (SUV) of greater than 2) was included as part of
gross tumor volume (GTV). For patients without fiducial
markers or tumors not large enough to be seen and
tracked using orthogonal radiographs, a 4D CT of the
chest was used to account for tumor motion and create an
internal target volume (ITV). The ITV was expanded
3–5 mm to account for set up error and arrive at the planning target volume (PTV). The total dose was prescribed
to the 80 % isodose volume. The median biological BED
used in this study was 105.6 Gy (range, 180–85.5 Gy10).
Organs at risk and their respective tolerance doses used
during treatment planning are shown in Table 1.
Three image guidance systems onboard the Cyberknife
platform were used: the XSight Spine Tracking System,
which relies on bony anatomy of the spine to locate and
Table 1 Organ tolerance dose limits
Organ total dose volume
Spinal cord

22 Gy Maximum

To any point

Esophagus

27 Gy maximum

To any point

Brachial plexus

24 Gy maximum

To any point

Aorta

45Gy maximum

To any point

Heart

30Gy maximum

To any point

Trachea and bronchus

30 Gy maximum

To any point

Chest wall/ ribs

30 Gy maximuma

Both lungs
Both Lungs
Skin
a

To any point

20 Gy

<10 % of organ volume

15 Gy

<35 % of organ volume

24 Gy maximuma

To any point

considered for superficial tumors < 2 cm from chest wall
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track tumors; the Synchrony Respiratory Motion Tracking
System, which continuously synchronizes beam delivery
with the motion of the target resulting from respiration by
using external fiducial markers as a surrogate to track
tumor motion; and the XSight Lung Tracking System,
which tracks the soft tissue (tumor) target with respiration
without the need for fiducial markers [13].
Statistical analysis

Statistical objectives of this study included the estimation
of median time until local progression, disease-free survival, all-cause mortality and acute toxicity. Survival was
measured using the Kaplan-Meier method to characterize
the progression of disease, local control and survival distributions. Median time to the event was estimated along
with a 95 % confidence interval (CI). The Cox proportional hazards regression model was used to study the effects of multiple predictor variables (e.g. tumor size, stage,
histology, patient age, tumor location (lobe), tracking
method and biologic effective dose (BED)) on these three
time-until-event outcomes. Descriptive statistics (proportions for categorical variables and means and standard
deviations for continuous variables) were also calculated.
Survival time was measured in months. Time until death
was calculated from date of treatment completion to
either date of event, or date of censoring (date of last
follow-up), except for local failure at first follow-up scan
post-treatment. In this case, time until death was measured from the date of first follow-up scan and not the
date of treatment completion. For disease-free survival,
failure was defined as any of the following: local failure,
regional failure, distant failure, or locoregional failure. In
cases where the event of death was not observed, the
number of months until last follow-up was used and the
subject’s vital status was classified as censored. The effects
of categorical demographic, clinical, pathologic, and treatment variables were assessed using the log-rank test.
Univariate Cox regression was used for continuous variables. A result was considered statistically significant if the
p value was <0.05. To adjust for tied failure times, Efron’s
method was used [14].
End points and follow-up

Approximately three months after completing treatment,
a follow-up radiologic examination was performed to determine the initial response to treatment. Two patients
were followed by a non-contrast CT and the remaining
with PET-CT scans. After the initial follow-up period, a
chest CT or PET-CT scan was done to evaluate both
tumor size and metabolism every 3 to 6 months for two
years post treatment ––after which follow-up was done
on an annual basis.
The definition of local control used in the current analysis was based on that used in RTOG 0236 [15]. Local
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failure was defined as meeting any one of the following
criteria: (1) local tumor enlargement greater than 20 %
of the gross tumor volume compared to the treatment
planning CT-scan, (2) evidence of increasing metabolism
using PET imaging, or (3) development of a new lesion
in the involved lobe [15]. Regional failure was defined as
a recurrence within a different ipsilateral lobe or any
regional lymph node station including the bilateral hilar,
mediastinal, scalene, or supraclavicular nodal stations as
defined in the American Joint Committee on Cancer
(AJCC) Cancer Staging Manual, 7th edition [16]. Distant
spread was defined as either radiographic evidence of a
malignant pleural or pericardial effusion, pleural-based
nodules, contralateral lung nodules, distant solid organ,
CNS or osseous involvement.

Results
A total of 67 medically inoperable patients with early
and intermediate stage lung cancer were treated with
stereotactic body radiotherapy (SBRT) between February
5, 2010 and November 4, 2013 (Table 2). Each patient
had a single peripheral tumor defined as at least 2 cm
from the trachea, carina and mainstem bronchi. One patient had limited follow-up, and was therefore included
only in the overall survival analysis. Of the remaining 66
patients: 43 had local control, 11 failed locally, 5 regionally, 2 distantly and 5 locoregionally. Twenty-two of the
67 subjects eventually died. Twenty-three of 66 subjects
had disease progression, and 6 had failed locally at the
time of initial post-treatment evaluation. The mean
follow-up was 24.5 months (range: 2.4-50.3 months).
Among subjects who remained alive or were censored,
the mean follow-up time was 28.6 months (range: 2.450.3 months).
Overall survival based on local control status at first
follow-up

All patients were imaged 1–6 months (median 3 months)
after treatment. Due to the variability in how long after
treatment a first follow-up scan was obtained, a sensitivity analysis was performed whereby the actual follow-up
time from treatment to time of scan was adjusted for in
a Cox regression model with local control status at time
of first scan as the predictor of interest. The results from
this analysis (data not shown) were similar to the Kaplan
Meier estimate thus, only the Kaplan Meier results are
reported as representative of local control status.
The achievement of local control at the time of initial
follow-up was significantly associated with improved
overall survival. Local control data were available for 66
patients. Among the 60 patients with local control determined at first follow-up, 16/60 died, whereas all 6 of the
subjects who failed locally at their first follow-up scan succumbed to their disease. The estimated 1 year survival
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Table 2 Patient characteristics (N = 67)
Age, years, median (range)

79 (60–92)

Sex

Male

n = 24 (36 %)

Female

n = 43 (64 %)

IA

n = 52 (78 %)

IB-III

n = 15 (22 %)

Left Lower lobe

n = 16 (24 %)

Left Upper Lobe

n = 16 (24 %)

Right Lower Lobe

n = 12 (18 %)

Right Upper Lobe

n = 23 (34 %)

<2.5 cc

n = 17 (25 %)

Stage

Location

Tumor volume

n = 19 (29 %)

5-2.5 cc

BEDa10
Tracking

Histology

5-10 cc

n = 7 (11 %)

10-20 cc

n = 9 (13 %)

>20 cc

n = 15 (22 %)

Mean

107.8

Median (Range)

105.6 (180–85.5)

XSight-spine

n = 30 (45 %)

XSight-lung

n = 3 (5 %)

XSight-spine + Fiducials

n = 34 (50 %)

Adenocarcinoma

n = 30 (44 %)

Squamous Cell Carcinoma

n = 14 (21 %)

Non-small cell lung carcinoma-NOSb

n = 14 (21 %)

Carcinoid

n = 3 (4 %)

Sarcomatoid mesothelioma

n = 1 (2 %)

Non-diagnostic biopsy

n = 6 (8 %)

Biologic Effective Dose, Gy10 or α/β ratio = 10
b
Not otherwise specified
a

probability among patients achieving local control was
86.2 % (95 % CI, 74.3-92.9), whereas the one year survival
probability for patients with local failure at first follow-up
scan was 0.0 % (95 % CI, not estimable) (Fig. 1).
Local control, disease-free and overall survival rates

At 12 months, 81.8 % (95 % CI, 67.3-90.3) of patients
maintained local control out of the total cohort. However,
by 24 months only 60.6 % (95 % CI, 41.5- 75.2) of patients
had local control although the median time to local progression of disease was never reached (Fig. 2). The overall
disease-free survival at 3 years was 37.5 % (95 % CI: 17.7
to 57.4). Median disease-free survival was estimated to be
28.5 months (95 % CI: 15.8 months to not reached)
(Fig. 3a). The overall survival at 3 years was 62.4 % (95 %
CI: 74.3-47.3 %). The median overall survival time was not
reached during the designated follow-up period (Fig. 3b).
Comparative analysis of survival outcomes

A comparison of survival outcomes stratified by various
patient and treatment-specific factors was not found to

be statistically significant (using the log-rank test and
p < 0.05). For example, analysis of time until disease progression with respect to gender (p = 0.8), stage (p = 0.16),
pathology (p = 0.1), or tumor location/lobe involved
(p = 0.15) did not reveal any significant differences
(Additional file 1: Figure S1). Similarly, non-significant
results were found in Cox regression analyses for BED10
(p = 0.43), age (p = 0.15), and tumor size (p = 0.66) with
respect to disease-free survival (data not shown).
Kaplan-Meier analysis for time until death was not
found to be statistically significant among the following
subgroups by univariate analyses: gender (p = 0.13), stage
(p = 0.37), pathology (p = 0.77), and tumor location/lobe
(p = 0.81) (Additional file 2: Figure S2). Results from a
univariate Cox regression analysis did not provide statistical evidence to suggest a difference in overall survival
according to BED10 (p = 0.08), age (p = 0.74), or tumor
size (p = 0.29) (data not shown).
Survival outcomes based on tracking method

A comparison of overall survival in patients stratified by
motion tracking and targeting system used during treatment was also done. Either non-invasive image guidance
(XSight-spine/lung) alone or XSight-spine followed by
matching to surgically implanted-intratumoral fiducials
was used to localize and track tumors during each fraction of treatment. In the latter technique, tumors were
initially aligned for treatment using the osseous spinal
anatomy of each patient as a surrogate (XSight-spine)
and then further adjusted through matching to radioopaque fiducials within the tumor. In the event that
tumor size was sufficient to visualize on orthogonal
radiographs, XSight-lung localization was utilized (3 patients out of 67) after an initial matching to a portion of
bony spine adjacent to the target. Survival was not found
to be statistically different in patients treated using
XSight-spine/lung compared to those treated with the
aid of XSight-spine localization with fiducials (Logrank,
p = 0.66). Additionally, there was no significant difference in local control or disease-free survival stratified by
any tumor tracking method (Logrank, p = 0.44 and
p = 0.97, respectively) (Fig. 4).
Treatment-related toxicity

Toxicity was assessed immediately after treatment and
again after 3 months of follow-up. Only four patients were
documented as developing grade 1 fatigue. No grade 2 or
higher toxicity was reported in this cohort at any time
(data not shown).

Discussion
In this study, medically inoperable patients with early or
intermediate-stage peripheral lung tumors were treated
with SBRT on a CyberKnife treatment platform to a range
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Months
Local failure at initial follow up
Fig. 1 Achieving initial local control in previously untreated, medically inoperable patients with peripheral tumors targeted with SBRT is a
predictor for improved survival. Comparing patients that achieved local control at first follow-up scan after SBRT was significantly associated with
overall survival (OS) (p < 0.0001). OS at one year was 86.2 % (95 % CI, 74.3-92.9) in those achieving initial local control, whereas the one year
survival probability for patients with local failure at first follow-up scan was 0.0 % (95 % CI, not estimable)

Local control probability
Fig. 2 Local control in previously untreated, medically inoperable patients with peripheral tumors after being treated with Cyberknife SBRT. Local
disease control at 12 months was 81.8 % (95 % CI, 67.3-90.3 %) and at 24 months was 60.6 % (95 % CI, 41.5- 75.2 %). The median time to local
progression of disease was not reached

Kelley et al. Radiation Oncology (2015) 10:120
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A

B

Overall survival, in months
Fig. 3 Disease free and overall survival in previously untreated patients with peripheral tumors deemed to be medically inoperable after being
treated with Cyberknife SBRT. a The median progression-free survival was estimated to be 28.5 months (95 % CI: 15.8 months to not reached).
The overall disease-free survival at 3 years was 37.5 % (95 % CI: 17.7- 57.4 %). b The overall survival at 3 years (36 months) was 62.4 % (95 % CI:
74.3-47.3 %). The median overall survival time was not reached

of biological effective doses (BED, 180–85.5 Gy10). The
overall survival in our cohort was similar to that achieved
in RTOG 0236 (62.4 % vs. 55.8 % at 36 months) [15]. Toxicity observed in this study, significant only for low grade
fatigue, was also improved when compared to earlier
studies—one of the first being the Indiana University
phase I dose escalation and feasibility trial with 5
treatment-related deaths (pneumonia (n = 3), respiratory

failure (n = 1), and hemoptysis (n = 1) occurring throughout the study period out of 70 patients treated with lung
SBRT to a total dose of 60-66Gy in three fractions [12]. In
light of these findings, we selected more conservative
doses in an effort to balance the risk of toxicity with the
efficacy of tumor control. In addition, we selected lower
doses based on others’ observations reporting comparable
3 year local control rates above 80 % at 2 years using BEDs

Kelley et al. Radiation Oncology (2015) 10:120
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B

A

Overall survival, in months

C

Fig. 4 Comparing local control, disease free and overall survival rates in patients stratified by motion tracking system used during Cyberknife
SBRT. Either a fiducial free (Xsight-spine/lung) or fiducial-based (Xsight-spine + fiducials) tracking system was used to localize and track tumors
during each fraction of treatment. In the later technique, patients were initially aligned with Xsight-spine and then further adjusted through
matching to intratumoral fiducials. a Overall Survival at 24 months was not statistically different in patients treated using Xsight-spine 69.2 %
(95 % CL: 82.1-50.3 %) compared using Xsight-spine with fiducials 76.2 % (95 % CL: 88.6-58.0 %) (Logrank, p = 0.66) There was also no significant
difference in b local control at 24 months for Xsight-spine alone 72.2 % (95 % CL: 94.8-49.6 %) vs. Xsight-spine with fiducials 52.3 % (95 % CL:
75.4-29.7 %) (Logrank, p = 0.44) or c disease free survival at 24 months when comparing Xsight-spine alone 51.4 % (95 % CL: 73.1-24.3 %) vs.
Xsight-spine with fiducials, 52.3 % (95 % CL: 72.1-27.6 %) (Logrank, p = 0.97)

Table 3 Selected studies comparing local control as a function of BED
Author, year

Stage

Dose, BED10

Local control

P value

Van der Voort van Zyp et al. 2009 [19]

T1, n = 35; T2, n = 24

180 Gy

96 % at 2 years

n.s. p = 0.197

112. 5 Gy

78 % at 2 years

Onimaru et al. 2008 [20]

Guckenberger et al. 2009 [21]

Bibault et al. 2012 [6]

Grills et al. 2012 [22]

Onishi et al. 2007 [23]

T1, n = 25; T2, n = 16
T1, n = 13; T2, n = 19; T3N0, n = 9
T1, n = 31; T2, n = 20
T1, n = 318; T2, n = 67; T3, n = 10
Stage I, n = 257

80 Gy

45 at 2 years

105.6 Gy

89 % at 2 years

>100 Gy

89 % at 3 years

<100 Gy

62 % at 3 years

≤150 Gy

70 % at 2 years

>150 Gy

100 % at 2 years

<105 Gy

85 % at 2 years

>105 Gy

96 % at 2 years

>100 Gy

84 % at 3 years

<100 Gy

37 % at 3 years

p = 0.0042
p = 0.0001
p = 0.006
p < 0.001
p <0.01
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that approximate the range used in our cohort [17, 18]. In
spite of these efforts, local control was lower than expected when compared to these historic controls.
We found that indeed, the local control rate at
24 months had decreased to 60.6 % compared to 91 % at
three years seen in RTOG 0236 [15]. Although minor deviations in treatment planning may have contributed to
this observation, the lower BEDs employed in this study
are thought to be contributing factors compared to those
used in earlier studies such as the Indiana University
phase I dose escalation trial and RTOG 0236 where BEDs
used were considerably higher— approaching 151.2
Gy10 once tissue heterogeneity corrections were applied
[15, 12]. Furthermore, several others have reported that
dose escalation correlated directly with significantly
improved local control rates (Table 3) [6, 19–23]. It should
also be emphasized that 22 % of the patients included
in our cohort had stage IB to stage III disease and
RTOG 0236 included patients with only T1-T2 tumors.
Thus, it is possible that this may contribute to the
lower local control rate seen in this study. Nevertheless,
caution must be exercised when interpreting these
results due to the limitations implicit within a retrospective study such as this. An additional limitation of
this study is the relatively small sample size (n = 67
patients/treated lung tumors) which may explain the
lack of statistical significance seen when performing a
comparative analysis of survival outcomes to identify
predictive factors (Additional file 1: Figure S1 and
Additional file 2: Figure S2).
As anticipated, patients that had achieved local control
initially at the time of first follow-up had significantly
improved overall survival compared with those that did
not. These data support the notion that achieving initial
local tumor control is of critical importance for survival.
Ablative therapies such as SBRT are now routinely designed without reliance on intra-target fiducial markers
since the advent of sophisticated onboard-non-invasive
image guidance systems [6, 13, 24]. Several phantom
studies have demonstrated the ability to achieve submillimeter targeting with these systems [25]. However,
evidence supporting the use of fiducial-free image guidance and localization systems is limited [6, 13, 25]. In
this analysis, through a side-by-side comparison, we
show that there is no difference statistically in survival
outcome or tumor control metrics when stratifying patients by tracking technique used. Thus, non-invasive
image-based tracking techniques appear to be safe and
effective alternatives compared with traditional fiducialbased targeting and is in agreement with others’ reports
[13, 18, 24, 25]. This has important implications in
medically inoperable, frail patient populations with lung
cancer that may not be able to easily tolerate such invasive procedures.
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Conclusions
This study supports the role of SBRT in the treatment
paradigm for early-stage lung cancer in medically inoperable patients in order to gain local control of their disease, and doing so appears to be critical to achieving
prolonged overall survival in this patient population. It
provides evidence to justify the use of non-invasive
tumor targeting during treatment administration over
invasive fiducial-based targeting methods. Lastly, the importance of dose escalation is emphasized by our results
especially with regard to the achievement of durable
local tumor control. Nevertheless, further studies evaluating higher dose fractionation schemes are warranted to
reach a comfortable equilibrium between better local
control and low treatment-related morbidity.
Additional files
Additional file 1: Figure S1. Comparison of disease free survival rates
in patients stratified by gender, stage, pathology and location. The
different Kaplan-Meier curves for time until disease progression were not
found to be statistically significant (using the log-rank test and p < 0.05)
among the following subgroups in univariate analysis: (A) Gender at 24
months comparing male patients, 49.3 % (95 % CL: 71.7-22.4 %) to female
54.3 % (95 % CL: 73.6-29.6 %), (p = 0.8), (B) Stage at 24 months comparing
early stage patients with T1a disease 47.8 % (95 % CL: 64.9-28.5 %) to
those with intermediate stage IB-III disease, 64.3 % (95 % CL: 90.2-15.2 %),
(p = 0.16), (C) pathology at 24 months for patients with adenocarcinoma
41.4 % (95 % CL: 66.2-15.2 %), squamous cell carcinoma 30.3 % (95 % CL:
61.6-5.3 %), and unspecified non-small cell lung 64.3 % (95 % CL: 90.2-15.2 %),
(p = 0.1) or (D) tumor location within the left lower lobe (LL), 50.1 % (95 % CL:
77.7-15.1 %), left upper lobe (LU), 73.7 % (95 % CL: 91.3-35.9 %) right lower
lobe (RL), 28.3 % (95 % CL: 60.0-44.0 %), or right upper lobe (RU) 46.4 % (95 %
CL: 75.2-12.6 %), (p = 0.15).
Additional file 2: Figure S2. Comparison of overall survival rates in
patients stratified by gender, stage, pathology and location. The different
Kaplan-Meier curves for overall survival were not found to be statistically
significant (using the log-rank test and p < 0.05) among the following
subgroups in univariate analysis: (A) gender at 24 months comparing
male patients, 87.1 % (95 % CL: 95.7-65.0 %) to female patients 65.9 %
(95 % CL: 78.3-49.2 %) (p = 0.8), (B) stage at 24 months comparing early
stage patients with T1a disease 69.7 % (95 % CL: 80.5-55.7 %) to those
with intermediate stage IB-III disease, 86.7 % (95 % CL: 96.5-56.4 %)
(p = 0.37), (C) pathology at 24 months for patients with adenocarcinoma
75.4 % (95 % CL: 87.5-55.2 %), squamous cell carcinoma 71.4 % (95 % CL:
88.2-40.6 %), and unspecified non-small cell lung 70.7 % (95 % CL:
87.9-39.4 %) (p = 0.77), or (D) tumor location within the left lower lobe
(LL), 68.8 % (95 % CL: 85.6-40.5 %), left upper lobe (LU), 68.2 % (95 % CL:
85.4-39.5 %), right lower lobe (RL), 90.0 % (95 % CL: 98.5-47.3 %), or right
upper lobe (RU), 73.9 % (95 % CL: 87.3-50.9 %) (p = 0.81).

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors contributed to the design, data collection, analysis and writing of
this work. All authors read and approved the final manuscript.

Acknowledgments
We would like to acknowledge and thank Dr. David Collingridge for his
valued advice and assistance in editing and critiquing this manuscript.

Kelley et al. Radiation Oncology (2015) 10:120

Submission
This material has never been published and is not currently under evaluation
in any other peer-reviewed publication. All authors have participated in the
clinical care, data acquisition and review, and preparation of this manuscript.
This work was presented at the September, 2014 American Society of
Radiation Oncology annual meeting in San Francisco, CA.
Author details
1
The Department of Radiation Medicine, North Shore-LIJ Cancer Institute,
Lake Success, NY, USA. 2The Department of Radiation Medicine, North
Shore-LIJ Health System, Huntington, NY, USA. 3The Department of
Biostatistics, Feinstein Institute for Medical Research, North Shore-LIJ Health
System, Manhasset, NY, USA. 4989W Jericho Turnpike, Smithtown, NY 11787,
USA.
Received: 26 January 2015 Accepted: 18 May 2015

References
1. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body
radiation therapy and its impact on current and future clinical practice.
J Clin Oncol. 2014;32:2847–54.
2. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung
cancer in patients not sufficiently fit for or declining surgery (medically
inoperable): a systematic review. Thorax. 2001;56:628–38.
3. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, et al.
American Society for Therapeutic Radiology and Oncology and American
College of Radiology practice guideline for the performance of stereotactic
body radiation therapy. Int J Radiat Oncol Biol Phys. 2004;60:1026–32.
4. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan N, Larson D, et al.
American Society for Therapeutic Radiology and Oncology (ASTRO) and
American College of Radiology (ACR) practice guideline for the
performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol
Phys. 2010;76:326–32.
5. Ryu S, Yoon H, Stessin A, Gutman F, Rosiello A, Davis R. Contemporary
treatment with radiosurgery for spine metastasis and spinal cord
compression in 2015. Radiat Oncol J. 2015;33:1–11.
6. Bibault J-E, Prevost B, Dansin E, Mirabel X, Lacornerie T, Lartigau E. Imageguided robotic stereotactic radiation therapy with fiducial-free tumor
tracking for lung cancer. Radiat Oncol. 2012;7:102.
7. Dosoretz D, Katin M, Blitzer P, Rubenstein J, Galmarini D, Garton G, et al.
Medically inoperable lung carcinoma: the role of radiation therapy.
Semin Radiat Oncol. 1996;6:98–104.
8. Stieb S, Lang S, Linsenmeier C, Graydon S, Riesterer O. Safety of high-doserate stereotactic body radiotherapy. Radiat Oncol. 2015;10:4–11.
9. Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD. Stereotactic Body
Radiation Therapy ( SBRT ) for lung cancer patients previously treated with
conventional radiotherapy: a review. Radiat Oncol. 2014;9:2–9.
10. Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM. Dose
escalation with stereotactic body radiation therapy boost for locally
advanced non small cell lung cancer. Radiat Oncol. 2013;8:179.
11. Yamashita H, Haga A, Takahashi W, Takenaka R, Imae T, Takenaka S.
Volumetric modulated arc therapy for lung stereotactic radiation therapy
can achieve high local control rates. Radiat Oncol. 2014;9:1–6.
12. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA,
et al. Stereotactic body radiation therapy for early-stage non-small-cell lung
carcinoma: four-year results of a prospective phase II study. Int J Radiat
Oncol Biol Phys. 2009;75:677–82.
13. Bahig H, Campeau M-P, Vu T, Doucet R, Béliveau Nadeau D, Fortin B, et al.
Predictive parameters of CyberKnife fiducial-less (XSight Lung) applicability
for treatment of early non-small cell lung cancer: a single-center experience.
Int J Radiat Oncol Biol Phys. 2013;87:583–9.
14. Hertz-Picciotto I, Rockhill B. Validity and efficiency of approximation
methods for tied survival times in Cox regression. Biometrics. 1997;53:1151–6.
15. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al.
Stereotactic body radiation therapy for inoperable early stage lung cancer.
JAMA. 2010;303:1070–6.
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer
Staging Manual. 7th ed. New York: Springer; 2010. p. 253–70.

Page 9 of 9

17. Brown WT, Wu X, Fayad F, Fowler JF, Amendola BE, García S, et al.
CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
Clin Lung Cancer. 2007;8:488–92.
18. Swangsilpa T, Yongvithisatid P, Pairat K, Dechsupa P, Dhanachai M,
Dangprasert S, et al. Preliminary experience of CyberKnife treatment of
primary non-small cell lung cancer. J Med Assoc Thai. 2012;95:1335–43.
19. Van der Voort van Zyp NC, Prévost J-B, Hoogeman MS, Praag J, van der Holt
B, Levendag PC, et al. Stereotactic radiotherapy with real-time tumor
tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol.
2009;91:296–300.
20. Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, et al.
Steep dose–response relationship for stage I non-small-cell lung cancer
using hypofractionated high-dose irradiation by real-time tumor-tracking
radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:374–81.
21. Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al. Dose –
response relationship for image-guided stereotactic body radiotherapy of
pulmonary tumors : relevance of 4D dose calculation. Int J Radiat Oncol.
2009;74:47–54.
22. Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al.
A collaborative analysis of stereotactic lung radiotherapy outcomes for
early-stage non–small-cell lung cancer using daily online cone-beam
computed tomography image-guided radiotherapy. J Thorac Oncol.
2012;1382–1393.
23. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al.
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I
non-small cell lung cancer: updated results of 257 patients in a Japanese
multi-institutional study. J Thorac Oncol. 2007;2:94–100.
24. Bahig H, Filion E, Vu T, Roberge D, Lambert L, Bouchard M, et al. Excellent
Cancer Outcomes Following Patient-adapted Robotic Lung SBRT But a Case
for Caution in Idiopathic Pulmonary Fibrosis. Technol Cancer Res Treat.
2014. Epub ahead of print.
25. Bibault JE, Prevost B, Dansin E, Mirabel X, Lacornerie T, Dubus F, et al.
Stereotactic radiotherapy for lung cancer: non-invasive real-time tumor
tracking. Cancer Radiother. 2010;14:690–7.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

